More recently, a better understanding of the biological heterogeneity of mPC in terms of drivers of tumor progression has revealed that a significant proportion (20–30%) of mCRPCs is characterized by DNA repair defects, making these tumors more sensitive to platinum salts [26] or to PARPi [27,28,29,30], especially in the case of BRCA2 mutations [31,32]. The gene discussed is BRCA2; the disease is neoplasm.